HARMONY BIOSCIENCES HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.42 USD | -0.08% |
|
+5.57% | +5.84% |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||
Pharmaceuticals | 6M | 160M | 305M | 438M | 582M | |
Total Assets | 107M | 427M | 433M | 674M | 811M | |
Interest Expense | -6.07M | -28.22M | -23.97M | -15.67M | -23.76M | |
Income Tax Expense | - | - | 2.83M | -76.78M | 44.54M | |
CAPEX | -127M | -2M | -100M | -40.17M | -312K | |
EBT | -152M | -36.94M | 37.43M | 105M | 173M | |
Gross Profit | 4.42M | 132M | 250M | 354M | 461M | |
D&A | 3.21M | 10.24M | 18.84M | 23.38M | 24.36M | |
Operating Income | -146M | 16.99M | 87.53M | 120M | 192M | |
Net Income | -152M | -36.94M | 34.6M | 181M | 129M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
United States (U.S.) | 6M | 160M | 305M | 438M | 582M | |
Total Assets | 107M | 427M | 433M | 674M | 811M | |
Interest Expense | -6.07M | -28.22M | -23.97M | -15.67M | -23.76M | |
Income Tax Expense | - | - | 2.83M | -76.78M | 44.54M | |
D&A | 3.21M | 10.24M | 18.84M | 23.38M | 24.36M | |
CAPEX | -127M | -2M | -100M | -40.17M | -312K | |
Gross Profit | 4.42M | 132M | 250M | 354M | 461M | |
Net Income | -152M | -36.94M | 34.6M | 181M | 129M | |
EBT | -152M | -36.94M | 37.43M | 105M | 173M | |
Operating Income | -146M | 16.99M | 87.53M | 120M | 192M |
- Stock Market
- Equities
- HRMY Stock
- Financials Harmony Biosciences Holdings, Inc.
- Business Segments